Leqembi Research Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2024, 2024-2029F, 2034F - ResearchAndMarkets.com

The "Leqembi Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's offering.

This Leqembi market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Leqembi is a prescription medication used to treat Alzheimer's disease. This drug is specifically designed to address the progressive neurodegenerative disorder, which leads to memory loss, cognitive decline, and difficulties in daily functioning. Leqembi works by targeting the underlying cause of Alzheimer's, reducing amyloid-beta plaques in the brain that are thought to contribute to the disease's progression.

The key company operating in the leqembi market is Eisai Co. Ltd. North America was the largest region in the leqembi market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in leqembi report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the leqembi market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The growth observed during the historic period can be attributed to factors such as an increase in the elderly population, higher funding allocations by governments and organizations for neurodegenerative disease research, improvements in reimbursement and coverage, ongoing clinical trial results, and a rise in healthcare spending.

Market growth during the forecast period is driven by factors such as increased research and development investments, greater awareness of early Alzheimer's diagnosis, the growing global prevalence of Alzheimer's disease, a higher demand for treatments for neurodegenerative disorders, and a stronger focus on reducing amyloid plaques. Key trends expected in the forecast period include advancements in neuroscience research, the rise of digital health technologies, improvements in Alzheimer's treatments, a shift towards personalized medicine, and the development of disease-modifying therapies.

The rising prevalence of Alzheimer's disease is expected to drive the growth of the leqembi market. Alzheimer's is a degenerative brain disorder that progressively impacts memory, cognition, and behavior, severely affecting daily life. The development of Alzheimer's disease is influenced by a combination of genetic, lifestyle, and environmental factors. Leqembi works by reducing beta-amyloid plaques in the brain, which helps slow cognitive decline in the early stages of Alzheimer's by targeting these plaques and preserving memory and cognitive functions.

For example, in September 2024, the European Brain Council, a Belgium-based international health organization, reported that approximately 7 million people in Europe are living with Alzheimer's, with this number expected to double to 14 million by 2030 due to the aging population, making it a significant global public health challenge. As a result, the increasing prevalence of Alzheimer's disease is contributing to the expansion of the leqembi market.

The leqembi market is being driven by advancements in intravenous (IV) maintenance dosing formulations for Alzheimer's treatment. This approach involves delivering a consistent or recurring dose of medication directly into the bloodstream, ensuring sustained therapeutic levels over time. For instance, in June 2024, Eisai Co., Ltd., a Japan-based pharmaceutical company, and Biogen Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had accepted a supplemental biologics license application (sBLA) for a monthly IV maintenance dosing regimen of LEQEMBI. This treatment targets toxic amyloid proteins, particularly protofibrils, which are believed to play a role in cognitive decline in Alzheimer's disease. LEQEMBI has demonstrated clinical and biomarker benefits, potentially extending treatment efficacy, reducing neuronal damage, and improving long-term patient outcomes.

In November 2024, Biogen Inc. and Eisai Co., Ltd. formed a partnership to develop and commercialize treatments for Alzheimer's disease, with a focus on Leqembi (lecanemab) for patients in the early stages of the disease. Eisai Co. Ltd. is the pharmaceutical company responsible for manufacturing leqembi.

The primary types of leqembi formulations are injectable forms, including intravenous injections and ready-to-use solutions. The intravenous injectable formulation delivers the medication directly into the bloodstream for rapid absorption and precise dosing, making it ideal for patients with advanced stages of the disease or those requiring consistent medication levels. It is used for various indications, including the treatment of Alzheimer's disease, management of mild cognitive impairment, and other conditions. It is suitable for adult, geriatric, and early-stage Alzheimer's patients. Leqembi is distributed through direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies, and is utilized by hospitals, neurology clinics, memory care facilities, and home healthcare providers.

Key Topics Covered:

1. Executive Summary

2. Leqembi Market Characteristics

3. Leqembi Market Biologic Drug Characteristics

3.1. Molecule Type

3.2. Route of Administration (ROA)

3.3. Mechanism of Action (MOA)

3.4. Safety and Efficacy

4. Leqembi Market Trends and Strategies

5. Leqembi Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market

6. Global Leqembi Growth Analysis and Strategic Analysis Framework

6.1. Global Leqembi PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

6.2. Analysis of End Use Industries

6.3. Global Leqembi Market Growth Rate Analysis

6.4. Global Leqembi Historic Market Size and Growth, 2019-2024, Value ($ Million)

6.5. Global Leqembi Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Million)

6.6. Global Leqembi Total Addressable Market (TAM)

7. Global Leqembi Pricing Analysis & Forecasts

8. Leqembi Market Segmentation

8.1. Global Leqembi Market, Segmentation by Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

• Injectable Formulation (Intravenous)
• Ready-To-Use Solutions

8.2. Global Leqembi Market, Segmentation by Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

• Treatment of Alzheimer's Disease
• Management of Mild Cognitive Impairment
• Other Neurodegenerative Disorders

8.3. Global Leqembi Market, Segmentation by Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

• Adult Patients
• Geriatric Patients
• Patients With Early-Stage Alzheimer's Disease

8.4. Global Leqembi Market, Segmentation by Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

• Direct Sales
• Wholesalers and Distributors
• Retail Pharmacies
• Online Pharmacies

8.5. Global Leqembi Market, Segmentation by End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

• Hospitals
• Neurology Clinics
• Memory Care Facilities
• Home Healthcare Providers

9. Global Leqembi Epidemiology of Clinical Indications

9.1. Drug Side Effects

9.2. Incidence and Prevalence of Clinical Indications

10. Leqembi Market Regional and Country Analysis

10.1. Global Leqembi Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

10.2. Global Leqembi Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

For more information about this report visit https://www.researchandmarkets.com/r/h5fj0h

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250514412471/en/